Actas dermo-sifiliograficas最新文献

{"title":"Use of an Alar Cartilage Chondromucosal Graft for Posterior Lamella Reconstruction in Full-Thickness Lower Eyelid Defects","authors":"E. Samaniego González , E. Pérez Díez , M. Cuesta Lasso , M. Criado Otero","doi":"10.1016/j.ad.2025.104542","DOIUrl":"10.1016/j.ad.2025.104542","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104542"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Topical Carbonic Anhydrase Inhibitors: A Literature Review","authors":"L. Aguilar-González, G. Gallo-Pineda, I. Villegas-Romero, M. Viedma-Martínez","doi":"10.1016/j.ad.2025.104528","DOIUrl":"10.1016/j.ad.2025.104528","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104528"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145706929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry","authors":"R. Rivera-Díaz ,&nbsp;A. Quesada ,&nbsp;A. Sahuquillo-Torralba ,&nbsp;E. Daudén ,&nbsp;J.M. Carrascosa ,&nbsp;I. Belinchón ,&nbsp;F.J. Gomez Garcia ,&nbsp;E. Herrera Acosta ,&nbsp;D.P. Ruiz Genao ,&nbsp;O. Baniandrés Rodriguez ,&nbsp;M. Ferrán Farres ,&nbsp;P. de la Cueva Dobao ,&nbsp;L.R. Fernández-Freire ,&nbsp;A. Mateu Puchades ,&nbsp;J. Riera-Monroig ,&nbsp;J.C. Ruiz Carrascosa ,&nbsp;M. Ara Martín ,&nbsp;M. Abalde Pintos ,&nbsp;M. Roncero Riesco ,&nbsp;J.L. Lopez-Estebaranz ,&nbsp;M. Angel Descalzo","doi":"10.1016/j.ad.2025.104588","DOIUrl":"10.1016/j.ad.2025.104588","url":null,"abstract":"<div><div>Interleukin 12/23 inhibitors (IL12/23i) and interleukin 17 and 23 inhibitors (IL17i and IL23i) represent the drug classes with the most favorable expectations for therapeutic response. However, the introduction of biosimilars has led many centers, for reasons of efficiency, to prioritize tumor necrosis factor inhibitors (TNFi) as first-line therapy. Data on whether prior exposure to TNFi may affect the drug survival of IL17i and IL23i therapies are lacking. Using data from the Biobadaderm registry, we compared treatment persistence among patients with psoriasis who received IL17i or IL23i as first-line therapy and those who received these agents after prior TNFi treatment. Rates of treatment discontinuation and adverse events (AEs) were compared between groups. Results showed that overall drug survival was higher in patients treated first line with IL17i or IL23i vs those treated after TNFi exposure. However, no significant differences were observed between groups in treatment discontinuation due to inefficacy or serious AEs. Overall AE rates were similar, with no differences in serious AEs or serious infections. Although global AE rates and discontinuation due to AEs were higher in patients previously on TNFi who subsequently received IL17i or IL23i vs biologic-naïve patients, these differences did not reach statistical significance. In conclusion, this study suggests that prior exposure to TNFi may influence the persistence of IL17i and IL23i therapies in patients with psoriasis.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104588"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145891736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study","authors":"M. Mansilla-Polo ,&nbsp;M. Pons-Benavent ,&nbsp;P. Fernández-Crehuet ,&nbsp;E. Vilarrasa ,&nbsp;C. Albanell-Fernández ,&nbsp;E. Morales-Tedone ,&nbsp;F. Rausell-Félix ,&nbsp;R. Alcalá-García ,&nbsp;M. Matellanes-Palacios ,&nbsp;G. Martín-Ezquerra ,&nbsp;F. Alfageme ,&nbsp;C. Ciudad-Blanco ,&nbsp;M.T. López-Villaescusa ,&nbsp;J.M. Segura-Palacios ,&nbsp;J.C. Pascual-Ramírez ,&nbsp;M.L. Fernández-Díaz ,&nbsp;D. Falkenhain-López ,&nbsp;M. García-Gil ,&nbsp;A. Agustí-Mejías ,&nbsp;N. No-Pérez ,&nbsp;A. Molina-Leyva","doi":"10.1016/j.ad.2025.104531","DOIUrl":"10.1016/j.ad.2025.104531","url":null,"abstract":"<div><h3>Background</h3><div>Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European Medicines Agency (EMA) for the treatment of hidradenitis suppurativa (HS).</div></div><div><h3>Objectives</h3><div>To assess the safety and efficacy profile of bimekizumab in patients with moderate-to-severe HS across multiple centers in Spain.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study including 84 patients treated with bimekizumab. Efficacy was assessed using an intention-to-treat approach, with patients who discontinued treatment for any reason or were lost to follow-up considered nonresponders. Data were collected at baseline, week 16, and week 24.</div></div><div><h3>Results</h3><div>The analysis included a total of 84 patients at 16 weeks, with 43 having completed the 24-week follow-up assessment (56 men [66.67%] and 28 women [33.33%]) with a mean age of 44.17 (13.43) years and a mean baseline IHS4 of 23.75 (12.87) were included. By week 24, IHS4 scores dropped by 16.73 points (<em>p</em> <!-->&lt;<!--> <!-->0.0001); a HiSCR50 of 55.95% was achieved at week 16, which was maintained with a HiSCR50 of 55.81% at week 24; DLQI scores improved by 10.67 points (<em>p</em> <!-->&lt;<!--> <!-->0.0001); pain scores dropped by 3.42 points (<em>p</em> <!-->&lt;<!--> <!-->0.0001); and flare counts were reduced by 1.53 (<em>p</em> <!-->=<!--> <!-->0.0006). Adverse events were reported in 20.24% of patients by week 16, mainly candidiasis, and dropped to 11.90% by week 24. 53.57% (45/84) of patients achieved IHS4-55 by week 16, and by week 24, 60.47% (26/43) of patients maintained or reached this response level.</div></div><div><h3>Conclusions</h3><div>Bimekizumab is effective for the treatment of HS in real-world clinical practice, with a manageable safety profile over the 24-week period. Our findings are consistent with those reported in phase 3 clinical trials.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104531"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypopigmented Lesions in a Patient With Metastatic Breast Cancer","authors":"J.F. Orts Paco,&nbsp;J.P. Serrano Serra,&nbsp;B. Rebollo Caballero","doi":"10.1016/j.ad.2025.104534","DOIUrl":"10.1016/j.ad.2025.104534","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104534"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlap Between Psoriasis and Atopic Dermatitis: Therapeutic Approach","authors":"F. Tous-Romero,&nbsp;C. Calvo-Asín","doi":"10.1016/j.ad.2025.104541","DOIUrl":"10.1016/j.ad.2025.104541","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104541"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145720032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatoscopic Findings of Adverse Nail Effects in Cancer Patients: Observational Study of 140 Patients","authors":"C. Laso-Leizcano ,&nbsp;A. Gavillero ,&nbsp;L. Navarro-Campoamor ,&nbsp;T. García-Lozano ,&nbsp;E. Nagore","doi":"10.1016/j.ad.2025.104540","DOIUrl":"10.1016/j.ad.2025.104540","url":null,"abstract":"<div><h3>Background</h3><div>Chemotherapy can cause multiple dermatological alterations, including nail changes that significantly impact patients’ quality of life. This study aims to characterize the nail alterations induced by chemotherapy and assess their diagnosis through dermatoscopy.</div></div><div><h3>Methodology</h3><div>An observational, prospective, and descriptive study that included 140 patients from the Fundación Instituto Valenciano de Oncología (FIVO). Both clinical and dermatoscopic nail alterations in the hands and feet were evaluated, associated with the different chemotherapy drugs administered. Analyzed variables included the type of nail alteration, the treatment cycle in which they appeared, and the observed dermatoscopic patterns.</div></div><div><h3>Results</h3><div>The prevalence of nail alterations was 45.7%, with chromonychia being the most frequent, followed by onycholysis. Lesions affected both hands and feet in 72.3% of cases. The most common chromonichias were erythronychia (36.4%) and leukonychia (9.3%). Monoclonal antibodies, tubulin binders, and platinum complexes were the drug groups most associated with these alterations. Onychomycosis was suspected in eight patients, confirmed in four cases through mycological cultures, where non-dermatophyte fungi were isolated.</div></div><div><h3>Conclusion</h3><div>Nail alterations induced by chemotherapy are common, affecting nearly half of patients. Dermatoscopy allowed the identification of alterations at early stages, which can facilitate the implementation of timely therapeutic strategies and improve patients’ quality of life.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104540"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145720081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Cutaneous Signs of Hipersensitivity to Drugs in a Pediatric Hospital","authors":"M. Suárez-Bustamante Huélamo ,&nbsp;J.A. Alonso-Cadenas ,&nbsp;L. Noguera Morel ,&nbsp;C. Escudero Diez ,&nbsp;R. Jiménez García ,&nbsp;M. de la Torre Espí","doi":"10.1016/j.ad.2025.104586","DOIUrl":"10.1016/j.ad.2025.104586","url":null,"abstract":"<div><h3>Background</h3><div>An adverse drug reaction (ADR) is a harmful and unintended response to drugs administered in therapeutic doses. Among these, cutaneous adverse reactions (CARs) are one of the most frequent clinical forms, which may occasionally be severe (SCARs).</div></div><div><h3>Objectives</h3><div>To describe the epidemiology of SCARs managed in a pediatric hospital.</div></div><div><h3>Methods</h3><div>A retrospective observational study of patients under 18 years of age who presented with a SCARs between January 1, 2011, and December 31, 2022. Exclusion criteria: immunosuppression, IgE-mediated allergic reactions, incomplete data, and no need for hospitalization.</div></div><div><h3>Results</h3><div>Of the 2433 patients diagnosed with a CAR, 34 (1.4%) presented with a SCAR. The main drugs involved were antibiotics, followed by NSAIDs and anticonvulsants. In 97.1% of cases (33 patients), the reason for prescribing the medications was an acute pathology. The final diagnoses were as follows: severe maculopapular rash in 21 patients, DRESS syndrome in 6, generalized exanthematous pustulosis in 3, erythema multiforme in 2, Stevens–Johnson syndrome in 1 and toxic epidermal necrolysis in 1. Two patients (5.9%) had a poor outcome. No deaths were reported in this series.</div></div><div><h3>Conclusion</h3><div>SCARs are very rare in pediatrics with a predominance of severe maculopapular rash. Clinical outcomes are generally favorable, although approximately 5% may present acute complications or sequelae, some of which may be severe. Therefore, upon initial suspicion of any of these SCARs, the potentially causal drugs should be immediately discontinued.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104586"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145832093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Approach to Direct Visualization of Methylene Blue-stained Urethral Specimens in Cases of Symptomatic Urethritis","authors":"A. Fernández-Galván ,&nbsp;M. Seguí-Olmedilla ,&nbsp;F.J. Bru-Gorraiz ,&nbsp;A. Martin-Gorgojo","doi":"10.1016/j.ad.2025.104536","DOIUrl":"10.1016/j.ad.2025.104536","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104536"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected End of a Hypochromic Macule","authors":"L.S. Costa ,&nbsp;B. Obere ,&nbsp;J. Tiscornia","doi":"10.1016/j.ad.2025.104533","DOIUrl":"10.1016/j.ad.2025.104533","url":null,"abstract":"","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 3","pages":"Article 104533"},"PeriodicalIF":2.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145740458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}